Angiotensin IV–related cognitive research peptide
N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide
A synthetic peptide studied for neurotrophic and cognitive effects via HGF/c-Met pathway research; human clinical evidence remains very limited.
- Evidence:
- Preclinical evidence primarily
- Status:
- Research-stage
- Reviewed:
- 2026-08-03
Also known as: PNB-0408, N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide
What is N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide?
A synthetic peptide studied for neurotrophic and cognitive effects via HGF/c-Met pathway research; human clinical evidence remains very limited.
This profile is educational. It organizes publicly discussed research context for N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide and related naming aliases — it is not a treatment guide.
Proposed mechanism
Proposed potentiation of hepatocyte growth factor (HGF)/c-Met signaling associated with synaptogenesis in preclinical models.
Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.
Current research notes
Human evidence grade: Preclinical evidence primarily
Preclinical evidence grade: Early-stage human research
Dihexa emerged from angiotensin IV analog research as a potential cognitive enhancer. Animal data suggest synaptic and memory-related effects; rigorous human trials are lacking. Research-chemical product quality varies.
Key uncertainties
- Human cognitive efficacy
- Long-term neurotrophic modulation safety
Research areas being studied
- Cognitive research
- Synaptogenesis
- Neurotrophic signaling
Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.
Safety & side-effect notes
Reported or discussed adverse effects
- Not characterized in humans
Additional risks & considerations
- Unknown human safety
- Unregulated research products
Regulatory status
Research-stage
Regulatory framing here is educational and can lag policy changes. Check official sources for current status.
Frequently asked questions
What is N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide?
A synthetic peptide studied for neurotrophic and cognitive effects via HGF/c-Met pathway research; human clinical evidence remains very limited.
How does N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide work (proposed mechanism)?
Proposed potentiation of hepatocyte growth factor (HGF)/c-Met signaling associated with synaptogenesis in preclinical models.
What is N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide being researched for?
N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide has been discussed in research contexts including: Cognitive research, Synaptogenesis, Neurotrophic signaling.
What does current evidence say about N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide?
Preclinical evidence primarily. Dihexa emerged from angiotensin IV analog research as a potential cognitive enhancer. Animal data suggest synaptic and memory-related effects; rigorous human trials are lacking. Research-chemical product quality varies.
What safety considerations are noted for N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide?
Reported or discussed considerations include: Not characterized in humans; Unknown human safety; Unregulated research products. This is educational information, not medical advice.
References & sources
- McCoy AT et al. (2013). Dihexa and HGF/c-Met cognitive research — J Pharmacol Exp Ther. Evidence type: animal.
Prefer interactive tools? Open the PepGuide library entry for N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide or ask PepGuide AI.
Educational and research information only. PepGuide does not sell or prescribe peptides, diagnose conditions, or provide personalized medical advice. Evidence summaries may include early-stage, animal, or limited human research — none of that is a substitute for primary literature or clinician guidance.